Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
No Thumbnail Available
Identifiers
Date
2022
Authors
De Laurentiis, Michelino
Borstnar, Simona
Campone, Mario
Warner, Ellen
Bofill, Javier Salvador
Jacot, William
Dent, Susan
Martin, Miguel
Ring, Alistair
Cottu, Paul
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
